MedTrace Logo

Compare Two Different Sclerosing Agents in the Treatment of Venous Malformations

NCT01347294 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 135

Last updated 2023-11-07

No results posted yet for this study

Summary

The purpose of this study is to determine the effectiveness of bleomycin, fibrovein and bleomycin and fibrovein in the treatment of venous malformation.

Conditions

  • Venous Malformation

Interventions

DRUG

Bleomycin

Intralesional

DRUG

Fibrovein

Intralesional

DRUG

Bleomycin + Fibrovein

Intralesional

Sponsors & Collaborators

  • Oslo University Hospital

    lead OTHER

Principal Investigators

  • Andreas Abildgaard, Phd · Oslo Universitetssykehus, Rikshospitalet

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
FACTORIAL

Eligibility

Min Age
12 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-08-31
Primary Completion
2023-11-30
Completion
2025-06-30

Countries

  • Norway

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01347294 on ClinicalTrials.gov